Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Pillai, D. Griffiths, R. Edgar, R. Stockley (Birmingham, United Kingdom). Symptom/risk assessment in alpha-1-antitrypsin deficiency (AATD) using the 2011 GOLD algorithm. Eur Respir J 2012; 40: Suppl. 56, 3214

Member's Comments

No comment yet.

Related content which might interest you: Predicting clinical course of alpha 1 anti-trypsin deficiency (AATD) using GOLD 2011 classification Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Prevalence of alpha-1-antitrypsin deficiency (A1AD) in patients with COPD. Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021 Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD) Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases Year: 2011 Occupational exposure in alpha-1-antitrypsin deficiency (AATD) Source: Annual Congress 2008 - COPD and other environment-related lung diseases Year: 2008 External quality assessment (EQA) for laboratory diagnosis of alpha1-antitrypsin deficiency (AATD) – Program driven by the European Alpha-1-Research Collaboration (EARCO) network Source: Virtual Congress 2021 – Pathogenic progress in airway diseases Year: 2021 Clinical, functional, radiologic and quality of life characteristics in PI*SZ Alpha 1-Antitrypsin Deficiency (AATD) compared to PI*ZZ, PI*MZ and COPD without AATD: a retrospective cohort study. Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021 Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil Source: Annual Congress 2013 –Assessing the prevalence of COPD in the general population Year: 2013 Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006 Differences of disease phenotypes in individuals with alpha-1-antitrypsin deficiency with genotypes PiZZ and PiSZ - Analysis from the German registry Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010 Severity of lung disease in siblings with α-1-antitrypsin deficiency (AATD) Source: Annual Congress 2008 - COPD Year: 2008 Health status changes in alpha-1-antitrypsin deficiency (PiZ phenotype) over 3 years Source: Annual Congress 2003 - Alpha-1 antitrypsin deficiency and COPD Year: 2003 Proteinase 3 activity is present in sputum from subjects with alpha-1-antitrypsin deficiency (AATD) and COPD Source: Annual Congress 2012 - The smoking gun in COPD biology Year: 2012 Usefulness of COPD assessment test (CATÔ) for the management of COPD according to GOLD 2011 Source: Annual Congress 2012 - COPD: epidemiology and varia Year: 2012 Erythrocyte abnormalities in alpha-1-antitrypsin deficiency (AATD) patients Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009 Bronchiectasis but not emphysema is more prevalent in non-PiZ alpha-1 antitrypsin deficiency (AATD) COPD than in usual COPD Source: International Congress 2014 – Genetics and environmental factors underlying asthma and COPD Year: 2014 The impact of the three GOLD severity classifications of COPD (2001, 2011 and 2017) in the same population of patients. Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers Year: 2017 Comparison between population with severe (ZZ) and intermediate (MZ) alpha1-antitrypsin deficiency and established COPD Source: International Congress 2019 – Advances in clinical management of COPD Year: 2019